NCT04515290View on ClinicalTrials.gov

A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

May 7, 2020

Primary Completion Date

April 22, 2022

Study Completion Date

April 22, 2022

Conditions
Chronic Heart Failure
Interventions
DRUG

TSG-01

Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.

DRUG

TSG-01 and Placebo

One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.

DRUG

Placebo

Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.

Trial Locations (5)

200021

Shanghai Shuguang Hospital, Shanghai

210029

Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing

310006

Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou

450000

Henan Province Hospital of TCM, Zhengzhou

The first Affiliated Hospital of Henan University of CM, Zhengzhou

All Listed Sponsors
lead

Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.

INDUSTRY

NCT04515290 - A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease. | Biotech Hunter | Biotech Hunter